| abstract |
CCT5 binding molecules are provided, including anti-CCT5 antibodies and antigen binding fragments thereof, such as heavy chain Variable (VH) regions and single chain antibody fragments; and conjugates comprising the anti-CCT5 binding molecules, such as immunoconjugates and antibody-drug conjugates; and chimeric receptors, such as Chimeric Antigen Receptors (CARs), comprising the anti-CCT5 binding molecules. In some embodiments, the anti-CCT5 antibody or antigen-binding fragment thereof specifically binds to CCT 5. Genetically engineered cells expressing the CAR or CCT5 binding molecules and their use as in adoptive cell therapy are also provided. |